Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: A single-institution report

Supportive Care in Cancer

Volumn 16, Issue 2, 2008, Pages 209-214

  Addeo, Raffaele ^a   Nocera, Vincenzo ^a   Faiola, Vincenzo ^a   Vincenzi, Bruno ^b   Ferraro, Gabriella ^c   Montella, Liliana ^a   Guarrasi, Rosario ^a   Rossi, Eugenio ^a   Cennamo, Gregorio ^a   Tonini, Giuseppe ^b   Capasso, Elena ^c   Santini, Daniele ^b   Caraglia, Michele ^d   Del Prete, Salvatore ^a  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c ASL Napoli3 Arzano   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bone metastasis; Elderly patients; Pain; Quality of life; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

AGED; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; JAW DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VOMITING;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 38349121336     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0315-y     Document Type: Article

References (17)

1. Carteni G, Bordonaro R, Giotta F et al (2006) Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 11(7):841-848
2. Cella DF, Tulsky DS, Gray G et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570-579
3. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
4. Conte P, Guarnieri V (2004) Safety of intravenous and oral biphosphonates and compliance with dosing regimens. Oncologist 9(Suppl.4):28-37
5. Gridelli C (2007) The use of bisphosphonates in elderly cancer patients. Oncologist 12(1):62-71
6. Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785-1791
7. Hortobagyi GN, Theriault RL, Lipton A et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044
8. Marco RA, Sheth DS, Boland PJ, Wunder JS, Siegel JA, Healey JH (2000) Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am 82(5):642-651
9. Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377-387
10. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double blind, randomized trial. The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157
11. Rubens RD (1998) Bone metastases-the clinical problem. Eur J Cancer 34:210-213
12. Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
13. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild moderate or severe? Grading pain severity by its interference with function. Pain 61:277-284
14. Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous biphosphonates. Ann Oncol 17:897-907
15. Theriault RL (2003) Zoledronic Acid use in bone disease. Expert Rev Anticancer Ther 3(2):156-166
16. Yancik RM, Ries L (1998) Cancer and age: magnitude of the problem. In: Balducci L, Lyman GH (eds) Comprehensive geriatric oncology. Harwood Academic, London, pp 95-104
17. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986-989